JAZZ stock forecast, quote, news & analysis
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology... Show more
Jazz Pharmaceuticals (JAZZ) Stock Analysis: Approaching 52-Week Highs as Analysts Raise Targets Ahead of Q2 Earnings
Key Takeaways
- Jazz Pharmaceuticals shares closed at $252.86 on July 31, 2026, rising approximately 6.5% over the trailing 30-day period and nearly 25% over the last quarter.
- The stock traded near its 52-week high of $261.30, supported by a wave of analyst price target increases from firms including Wells Fargo, Needham, Jefferies, Deutsche Bank, and Canaccord Genuity.
- Q1 2026 results showed record revenue of $1.07 billion, up 19% year-over-year, driven by 45% growth in oncology and continued strength in the Xywav and Epidiolex franchises.
- Jazz is scheduled to report Q2 2026 earnings on August 3, 2026, with a key regulatory catalyst — the zanidatamab PDUFA date — set for August 25, 2026.
- Institutional ownership stands at approximately 89%, while insider selling under pre-arranged 10b5-1 plans has drawn some attention.
Current Market Snapshot
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) enters the early-August period trading near the upper end of its 52-week range, having climbed from the $203 level at the end of April 2026 to approximately $253 as of July 31. The stock's 50-day simple moving average sits around $235, while the 200-day moving average is near $201, reflecting a sustained uptrend. Investor sentiment has been buoyed by a series of bullish analyst actions throughout July, with price targets now ranging as high as $307 from Bank of America and $301 from Piper Sandler. The broader biopharmaceutical sector has shown resilience, but Jazz's distinct neuroscience and oncology profile, combined with tangible pipeline catalysts, has helped the stock outperform the broader market. With Q2 earnings due imminently and a key regulatory decision weeks away, trading volumes have reflected elevated institutional interest heading into these events.
Jazz Pharmaceuticals (JAZZ) Business Overview and Competitive Position
Jazz Pharmaceuticals is a global biopharmaceutical company headquartered in Dublin, Ireland, focused on developing and commercializing therapies in neuroscience and oncology for patients with serious diseases — often where limited or no therapeutic options exist. The company's flagship neuroscience products include Xywav (calcium, magnesium, potassium, and sodium oxybates) for cataplexy and excessive daytime sleepiness in narcolepsy and idiopathic hypersomnia, and Epidiolex (cannabidiol) for multiple forms of epilepsy. On the oncology side, Jazz markets Zepzelca (lurbinectedin) for metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Ziihera (zanidatamab-hrii) for HER2-positive biliary tract cancer. The company's pipeline features zanidatamab in development for gastric and gastroesophageal junction adenocarcinoma, as well as the recently acquired dordaviprone for H3 K27M-mutant diffuse glioma through the Chimerix acquisition. Jazz also markets Enrylaze (recombinant crisantaspase) and the recently launched Midevo, broadening its oncology footprint.
Recent Developments Driving JAZZ
Several converging factors have shaped the narrative around Jazz Pharmaceuticals in recent weeks. The most visible has been a concentrated wave of analyst upgrades and price target increases. Canaccord Genuity initiated coverage on July 16 with a Buy rating and a $290 price target. Needham raised its target from $255 to $282, while Wells Fargo lifted its target from $265 to $285 and reiterated an Overweight rating. Barclays, Jefferies, and Deutsche Bank all issued upward revisions during the same period. The consensus rating across 20 analysts stands at Moderate Buy to Strong Buy, with an average price target near $260.
Fundamentally, the company's Q1 2026 results provided a compelling growth narrative. Record quarterly revenue of $1.07 billion was fueled by a 45% surge in the oncology portfolio, with Zepzelca sales jumping 60% to $101 million. Xywav contributed $408 million with approximately 16,600 active patients, while Epidiolex delivered $250 million on 16% volume growth. The company reaffirmed full-year 2026 revenue guidance of $4.25–$4.50 billion.
On the regulatory front, the supplemental Biologics License Application for zanidatamab in gastric and gastroesophageal junction adenocarcinoma was accepted with Priority Review, and a PDUFA date has been set for August 25, 2026. The Horizon GEA trial showed a median overall survival of 26.4 months for the triplet arm, representing an improvement of more than six months compared to prior HER2-positive metastatic GEA studies. Institutional activity has also been notable, with Principal Financial Group increasing its stake by 3.8% in Q1 and the Illinois Municipal Retirement Fund boosting its position by 26.7%. Offsetting some of the positive flow, insider selling — including transactions by Director Bruce C. Cozadd and EVP Neena M. Patil under 10b5-1 plans — has occurred, though aggregate insider selling of approximately $3.1 million over 90 days remains modest relative to the company's $15.7 billion market capitalization.
Trending AI Robots
For investors seeking a data-driven edge in evaluating momentum and entry points in stocks like Jazz Pharmaceuticals, Tickeron's Trending AI Robots page offers a curated view of top-performing AI trading bots actively trading across thousands of tickers. These bots employ diverse strategies — from swing trading to trend following and pattern recognition — each calibrated to different timeframes and risk profiles. Only the most relevant and consistently high-performing bots appear in this section, giving users a filtered lens into where algorithmic strategies are identifying opportunity. Whether complementing fundamental analysis or offering an independent quantitative perspective, the Trending AI Robots page provides a practical starting point for traders looking to incorporate AI-driven insights into their process.
2026 Outlook and What Investors Should Watch
The most immediate catalyst for Jazz Pharmaceuticals is the Q2 2026 earnings report, which is expected to provide updated revenue figures, pipeline progress, and any adjustments to full-year guidance. Analysts anticipate Q2 revenue of approximately $1.11 billion and EPS estimates ranging from $5.24 to $6.18. Beyond earnings, the August 25, 2026 PDUFA date for zanidatamab in HER2-positive gastric and gastroesophageal junction adenocarcinoma represents a potential binary catalyst that could expand Jazz's oncology addressable market. Additional pipeline milestones include planned interim overall survival readouts from zanidatamab trials and the ACTION trial evaluating Midevo in earlier-line settings, with data expected in late 2026 or early 2027. Investors should also monitor competitive dynamics in the sleep medicine franchise as generic high-sodium oxybates and potential new wake-promoting agents enter the landscape, a headwind management has already flagged for the second half of 2026. The company's strong balance sheet, with $2.9 billion in cash and investments as of Q1, provides flexibility for business development and continued pipeline investment. Macroeconomic factors, including interest rate policy and healthcare regulatory shifts, remain relevant to the broader biopharma sector's valuation backdrop.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full Disclaimers and Limitations.
Aroon Indicator for JAZZ shows an upward move is likely
JAZZ's Aroon Indicator triggered a bullish signal on July 31, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 191 similar instances where the Aroon Indicator showed a similar pattern. In of the 191 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on July 21, 2026. You may want to consider a long position or call options on JAZZ as a result. In of 96 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for JAZZ just turned positive on July 21, 2026. Looking at past instances where JAZZ's MACD turned positive, the stock continued to rise in of 47 cases over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where JAZZ advanced for three days, in of 293 cases, the price rose further within the following month. The odds of a continued upward trend are .
Bearish Trend Analysis
The 10-day RSI Indicator for JAZZ moved out of overbought territory on July 09, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 25 similar instances where the indicator moved out of overbought territory. In of the 25 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 8 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where JAZZ declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
JAZZ broke above its upper Bollinger Band on July 21, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. JAZZ’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock slightly better than average.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.505) is normal, around the industry mean (19.620). JAZZ's P/E Ratio (2298.727) is considerably higher than the industry average of (38.277). Projected Growth (PEG Ratio) (0.941) is also within normal values, averaging (3.532). Dividend Yield (0.000) settles around the average of (0.020) among similar stocks. P/S Ratio (3.546) is also within normal values, averaging (420.906).
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a specialty biopharmaceutical company, which focuses on the identification, development and commercialization of pharmaceutical products
Industry Biotechnology